Zobrazeno 1 - 10
of 20 170
pro vyhledávání: '"Griffin, K."'
Autor:
Andrew V. Tran, John K. Stadler, Zachary Ernst, Caleb A. Smith, Danya Nees, Griffin K. Hughes, Matt Vassar
Publikováno v:
BMC Neurology, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Neurological disorders have had a substantial rise the last three decades, imposing substantial burdens on both patients and healthcare costs. Consequently, the demand for high-quality research has become crucial for exploring eff
Externí odkaz:
https://doaj.org/article/1e0426862d4e41fcbf7ae0fff8220469
Autor:
Nira Santana Montañez
Publikováno v:
PASOS Revista de Turismo y Patrimonio Cultural, Vol 16, Iss 3 (2018)
Externí odkaz:
https://doaj.org/article/e661d0b4f8654fb5bb4d25f7e604ab1a
Autor:
Alex Hagood, Logan Patrick Corwin, Jay S. Modi, Garrett A. Jones, Kyle J. Fitzgerald, Kimberly J. Magana, Shaelyn A. Ward, Trevor R. Magee, Griffin K. Hughes, Alicia Ito Ford, Matt Vassar
Publikováno v:
Contemporary Clinical Trials Communications, Vol 41, Iss , Pp 101347- (2024)
Main problem: Chronic kidney disease (CKD) is a progressive condition that affects millions of people worldwide. A standardized core outcome set (COS) was developed for CKD by the International Consortium for Health Outcomes and Measurements in 2019.
Externí odkaz:
https://doaj.org/article/36b5e03caf5c4a16835ae099970f5eb1
Autor:
Matt Vassar, Vinay Prasad, Ryan McIntire, Alyson Haslam, Brody Dennis, Chance Bratten, Griffin K Hughes, Andriana M Peña, Chase Ladd, Brooke Gardner, William Nowlin, Reagan Livingston, Jordan Tuia
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Objective Our objective of this study was to analyse all oncological clinical trials using regorafenib to create a complete risk/benefit profile for the drug.Background Creating a novel chemotherapy is costly both in time and capital spent for drug m
Externí odkaz:
https://doaj.org/article/7ca47621bd2a46d6b44ec10b8d27ec8d
Autor:
Hagood, Alex, Corwin, Logan Patrick, Modi, Jay S., Jones, Garrett A., Fitzgerald, Kyle J., Magana, Kimberly J., Ward, Shaelyn A., Magee, Trevor R., Hughes, Griffin K., Ford, Alicia Ito, Vassar, Matt
Publikováno v:
In Contemporary Clinical Trials Communications October 2024 41
Autor:
Hunter Hall, Rafe, Wright, Carson L., Hughes, Griffin K., Peña, Andriana M., Ladd, Chase, Gardner, Brooke, McIntire, Ryan, Ferrell, Matt, Rubenstein, Jane, Tuia, Jordan, Haslam, Alyson, Prasad, Vinay, Vassar, Matt
Publikováno v:
In Clinical Therapeutics June 2024 46(6):e107-e113
Autor:
Nira Santana Montañez
Publikováno v:
PASOS. Revista de Turismo y Patrimonio Cultural. 16:857-861
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb3b83dac9ad2b048add837cb8a76ba5
https://doi.org/10.25145/j.pasos.2018.16.061
https://doi.org/10.25145/j.pasos.2018.16.061
Autor:
Adam Khan, Hassan Khan, Griffin K. Hughes, Chase Ladd, Ryan McIntire, Brooke Gardner, Andriana M. Peña, Abigail Schoutko, Jordan Tuia, Kirstien Minley, Alyson Haslam, Vinay Prasad, Matt Vassar
Publikováno v:
Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)
Abstract Objective This study aims to evaluate published clinical trials of ramucirumab to assess the risk/benefit profile and burden over time for patients. Background The burden of oncologic drug development on patients paired with increasing clini
Externí odkaz:
https://doaj.org/article/f7f50920e6bb409a822baf9cf0fba3d2
Autor:
Bode, B. H.
Publikováno v:
The Philosophical Review, 1915 Jan 01. 24(1), 102-105.
Externí odkaz:
https://www.jstor.org/stable/2178533